Contamination of polydeoxyribonucleotide extracts with cellular debris and non-target nucleic acids. Reducing these impurities ensures biocompatibility and therapeutic efficacy in regenerative medicine.

Natural extracts often suffer from insufficient concentrations of active physiological components in their raw state. Increasing the yield and accessibility of these compounds overcomes the limitation of poor therapeutic efficacy.

Low natural concentrations of bioactive compounds in plant tissues limit commercial viability. Increasing metabolic output through elicitation enables industrial-scale production of phytoestrogens.